Compare Neurocrine Biosciences Inc (NBIX) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Neurocrine Biosciences Inc trades at $166.47 (market cap $16.76B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.52. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | XDTE | |
|---|---|---|
Market Cap | $16.76B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $185.50 | $44.76 |
52-Week Low | $123.10 | $36.00 |
Enterprise Value | $16.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
XDTE trades at $39.46, up 0.65% with bullish technical signals from moving averages. The ETF generates weekly dividend distributions but faces scrutiny over yield sustainability and NAV erosion despite S&P 500 highs. Recent coverage highlights structural concerns about whether distributions represent true income or return of capital.
The fund offers high weekly income but carries significant risks including potential capital erosion and tax inefficiency. While technical momentum appears positive, fundamental concerns about the covered call strategy's long-term viability warrant caution for income-focused investors seeking sustainable returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
